According to an American Academy of Ophthalmology news release, Edmond’s priorities during her term include addressing physician and staff shortages and protecting patient safety at a time when nonphysicians are trying to expand their scope of practice into eye surgery.
Company presenting data from the Phase II AAVIATE trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration January 16 at the Hawaiian Eye and Retina 2024 Meeting.
The company is showcasing its lasers at the Hawaiian Eye and Retina 2024 meeting, being held January 13-19 at the Grand Wailea Resort in Maui.
Studies aim to develop a clinically useful biomarker of retinal capillary changes to monitor the development of a prevalent form of systemic vascular disease and cerebrovascular disease.
Because acetylcholinesterase inhibitors have anti-inflammatory effects, authors of the study wanted to determine if these drugs reduce the risk of AMD in patients with Alzheimer’s disease.
The GLYCO Phase 2 US clinical trial will evaluate AVD-104 for the management of diabetic macular edema (DME).
The VISUMAX 800 is the latest generation of Zeiss femtosecond lasers, and offers a reduced laser time when compared to its predecessors.
AR-15512, a topical transient receptor potential melastatin 8 agonist, is a first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease. Alcon plans to file a New Drug Application for AR-15512 with the FDA in mid-2024.
According to the company, cyclosporine ophthalmic solution 0.1% is the first and only cyclosporine-based product for treating the signs and symptoms of dry eye disease.
Researchers at Indiana University School of Medicine will focus on providing a foundation for developing a new glaucoma therapeutic by testing human neurons and a regenerative therapy to rescue visual neurons from dying preclinically in human eyes under glaucoma conditions.
According to the company, all three patients treated for two years or more have remained free of symptoms and disease progression while taking gildeuretinol.
According to the company, EYP-1901 is an investigational sustained delivery therapy containing vorolanib, a selective tyrosine kinase inhibitor formulated in bioerodible Durasert E.
Student confidence in dealing with ophthalmic conditions is down, deterring them from considering ophthalmology as a career.
The company’s ANX007 global pivotal program in geographic atrophy is expected to start in mid-2024. It is the first pivotal trial to use vision preservation as a primary outcome measure in GA.
Sharing, learning, networking, collaborating
eSight’s medical equipment enhances vision for individuals with over 20 distinct ocular disorders, frequently enabling users to attain 20/20 vision. The Consumer Electronics Show runs January 9-12 in Las Vegas.
The Retina Program 2024 will convene during the Hawaiian Eye meeting in Maui from January 14 through January 19
According to OKYO Pharma, the first-in-human, randomized, double-masked, placebo-controlled trial of OK-101 “established a clear and informed path for further development in Phase 3 registration trials.”
The device is intended for use for LASIK vision correction surgery for myopia and myopic astigmatism.
Researchers found the administration of the neuropeptide α–melanocyte–stimulating hormone promotes corneal healing and restores normal eye function to an otherwise degenerating and diseased cornea by providing protection against cell death and promoting cell regeneration.
The company announced more advancements of its RASP modulator platform, including plans for ADX-629 and ADX-246.
This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.
Albert S Jun, MD, PhD, comes to UVA from the Johns Hopkins University School of Medicine.
Hawaiian Eye and Retina 2024 meetings will take place from January 13 to 19 at the Grand Wailea Maui, 3850 Wailea Alanui Drive, Wailea, HI.
The study will evaluate the safety and efficacy of fluocinolone acetonide intravitreal implant 0.18mg, (YUTIQ) in the treatment of chronic non-infectious uveitis and related intraocular inflammation.
The revision is in response to multiple recalls for eye drops and instances of consumer injury and death in 2023.
According to the company, Phase 3 startup activities are underway, and the clinical trial is expected to start in the first quarter of 2024.
A specialist in the field of ophthalmology and gene therapy, Dr Girach’s appointment enhances SpliceBio’s leadership team as it accelerates lead program targeting Stargardt disease towards clinical development.
The company is announcing 3 market access partnerships with PhilRx, Apollo Care, and PARx Solutions, expanding US availability of the solution.
According to a news release, the services will be provided for RetinalGeniX Technologies’ Institutional Review Board to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration.
.png "Optometry Times"){kind=logo}
